Phase II Study of Pharmacokinetic Model-Based ATG Dosing to Improve Survival through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex Vivo CD34-Selected Allogeneic HCT (PRAISE-IR)

Ex vivo CD34-selected allo-HCT is associated with favorable CRFS but limited by delayed immune reconstitution (IR) and in some trials higher non-relapse mortality (NRM) (BMT CTN 1301, JCO 2023). We recently reported that the use of traditional weight-based ATG dosing in this setting led to high post-HCT ATG pharmacokinetic (PK) exposure that was associated with delayed CD4+ T cell IR (CD4+IR) and increased NRM risk (Lakkaraja et al., Blood Adv 2022).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michael Scordo, Miguel-Angel Perales, Audrey Mauguen, Andrew Lin, Binni Kunvarjee, Linh Khanh Nguyen, Jennifer Bieler, Maria Paes Pena, Christina Cho, Boglarka Gyurkocza, Andrew C. Harris, Ann A. Jakubowski, Dr. Richard J. Lin, Esperanza B. Papadopoulos, Tags: LBA-1 Source Type: research